Bicocca Open Archive

Logo unimib boa
GAMBACORTI PASSERINI, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 32.763
AS - Asia 17.036
EU - Europa 15.485
SA - Sud America 2.506
AF - Africa 287
Continente sconosciuto - Info sul continente non disponibili 37
OC - Oceania 30
Totale 68.144
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 32.010
SG - Singapore 5.922
CN - Cina 3.993
IT - Italia 3.108
HK - Hong Kong 2.660
RU - Federazione Russa 2.633
DE - Germania 2.629
VN - Vietnam 2.601
BR - Brasile 2.038
IE - Irlanda 1.765
SE - Svezia 1.715
UA - Ucraina 1.063
GB - Regno Unito 806
CA - Canada 554
FI - Finlandia 410
IN - India 350
FR - Francia 337
ID - Indonesia 284
KR - Corea 282
TR - Turchia 257
AR - Argentina 212
PL - Polonia 166
AT - Austria 159
BD - Bangladesh 146
ZA - Sudafrica 134
MX - Messico 132
NL - Olanda 132
JP - Giappone 127
DK - Danimarca 119
BE - Belgio 104
ES - Italia 86
IQ - Iraq 85
EC - Ecuador 73
PK - Pakistan 49
CO - Colombia 45
LT - Lituania 40
VE - Venezuela 39
BG - Bulgaria 35
SA - Arabia Saudita 35
CZ - Repubblica Ceca 33
MA - Marocco 33
EU - Europa 32
IR - Iran 31
PE - Perù 30
CH - Svizzera 26
CL - Cile 26
UZ - Uzbekistan 26
EG - Egitto 25
PY - Paraguay 23
TN - Tunisia 23
RO - Romania 22
KE - Kenya 21
AU - Australia 18
MY - Malesia 18
AE - Emirati Arabi Uniti 17
GR - Grecia 16
JO - Giordania 16
PT - Portogallo 15
DO - Repubblica Dominicana 14
IL - Israele 14
PH - Filippine 14
NO - Norvegia 13
JM - Giamaica 12
NP - Nepal 12
AZ - Azerbaigian 11
KG - Kirghizistan 11
KZ - Kazakistan 11
MU - Mauritius 11
NZ - Nuova Zelanda 11
UY - Uruguay 11
RS - Serbia 10
BO - Bolivia 9
HN - Honduras 9
TT - Trinidad e Tobago 9
CR - Costa Rica 8
ET - Etiopia 8
PS - Palestinian Territory 8
DZ - Algeria 7
LB - Libano 7
SK - Slovacchia (Repubblica Slovacca) 7
AL - Albania 6
SC - Seychelles 6
TH - Thailandia 6
AM - Armenia 5
BH - Bahrain 5
EE - Estonia 5
LA - Repubblica Popolare Democratica del Laos 5
LV - Lettonia 5
BY - Bielorussia 4
GT - Guatemala 4
LK - Sri Lanka 4
OM - Oman 4
SY - Repubblica araba siriana 4
BN - Brunei Darussalam 3
BW - Botswana 3
CI - Costa d'Avorio 3
HR - Croazia 3
LU - Lussemburgo 3
MD - Moldavia 3
MK - Macedonia 3
Totale 68.097
Salva come PNG Salva come JPEG
Città #
Ann Arbor 6.174
Singapore 3.455
Woodbridge 2.706
Ashburn 2.702
Hong Kong 2.645
Fairfield 2.295
Dublin 1.721
Houston 1.641
Frankfurt am Main 1.503
Chandler 1.489
Wilmington 1.323
Milan 1.268
Jacksonville 1.045
Seattle 946
New York 834
Dearborn 794
Ho Chi Minh City 785
Cambridge 784
Santa Clara 749
Hefei 615
Beijing 608
Hanoi 599
Dallas 583
Princeton 564
Los Angeles 532
Nanjing 318
Shanghai 295
Moscow 270
Seoul 261
Altamura 249
Lawrence 249
Jakarta 238
Chicago 236
Buffalo 216
São Paulo 206
Göttingen 188
The Dalles 184
Munich 175
Lachine 173
Guangzhou 151
San Diego 142
Boardman 129
Toronto 122
Nuremberg 118
Helsinki 106
Lissone 101
Andover 98
Nanchang 98
Vienna 98
Brussels 97
Shenyang 95
Tokyo 95
London 94
Ottawa 92
Dong Ket 91
Warsaw 91
Rome 84
Council Bluffs 81
Fremont 81
Da Nang 79
Tianjin 77
Haiphong 74
Montreal 73
Changsha 71
Rio de Janeiro 70
Salt Lake City 70
Turku 69
Hebei 68
Fürstenwalde 65
Johannesburg 65
Chennai 62
Romola 62
Stockholm 62
Kent 61
Brooklyn 59
Jinan 58
Jiaxing 57
Denver 53
Quận Bình Thạnh 53
Lodz 52
Ha Long 51
Lappeenranta 50
Orem 50
Hải Dương 49
Biên Hòa 48
Falls Church 48
Ninh Bình 48
Poplar 48
Pune 47
Atlanta 46
Norwalk 46
Phoenix 46
Kocaeli 45
Boston 44
Mexico City 44
Kunming 42
Mountain View 42
Vũng Tàu 42
Curitiba 41
Düsseldorf 40
Totale 45.959
Salva come PNG Salva come JPEG
Nome #
Single-center study on SARS-CoV-2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization 613
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 509
Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations 501
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 452
A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data 444
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 436
CNS relapse risk in HIV-positive patients affected by DLBCL and HGBL – a retrospective study of the musthal cohort 431
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 406
Acute myeloid leukaemia niche regulates response to L-asparaginase 403
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 397
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 397
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 396
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 391
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 380
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 380
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions 379
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 378
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 376
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 371
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 367
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 364
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 357
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis 355
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 355
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 355
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 355
WHOLE-EXOME SEQUENCING OF A PHILADELPHIA NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENT THROUGH THE EXON-CAPTURE TECHNIQUE 352
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 351
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 349
A computational procedure to identify and annotate somatic mutations in next-generation sequencing data 346
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 345
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 344
Imatinib long term effects study: three years of follow-up and assessment 333
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 328
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 319
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 314
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 310
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 305
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 305
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 305
Chronic myeloid leukemia: Second-line drugs of choice 304
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 303
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 302
BCR-ABL nuclear entrapment kills human CML cells: Ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 298
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 297
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 297
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia 295
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 291
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 290
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 282
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al 282
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 280
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 279
Inhibition of RET tyrosine kinase by SU5416 279
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 279
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 278
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 276
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation 276
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 275
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 275
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 271
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy 271
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 271
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 271
Idiopathic erythrocytosis: a germline disease? 270
Whole-Exome Sequencing Data - Identifying Somatic Mutations 270
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 267
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 266
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 266
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 266
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 265
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 265
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 265
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 264
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 262
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 259
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients 259
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 258
The ALK gene, an attractive target for inhibitor development 253
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 252
ALK inhibitors for clinical use in cancer therapy 252
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 252
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias 251
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 251
Reply to P. Laneuville et al 250
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 248
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 247
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 247
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 247
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 246
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 245
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery 245
Increased sFLT-1/PlGF ratio in COVID-19: A novel link to angiotensin II-mediated endothelial dysfunction 245
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039) 242
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 238
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 236
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia 236
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 236
Remission of low-grade lymphomatoid granulomatosis with extensive pulmonary involvement following immune restoration via antiretroviral therapy in a newly diagnosed HIV patient 235
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 233
Totale 31.065
Salva come PNG Salva come JPEG
Categoria #
all - tutte 229.907
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 229.907
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.493 0 0 0 0 0 687 780 698 650 650 473 555
2021/20224.093 331 406 499 279 276 366 213 228 206 304 329 656
2022/20236.561 864 1.919 566 554 469 932 72 333 418 126 152 156
2023/20245.361 129 146 202 235 671 1.456 978 159 443 287 90 565
2024/202513.373 790 1.498 734 665 1.115 506 914 419 1.112 1.954 1.217 2.449
2025/202616.124 4.223 2.279 2.407 3.481 3.379 355 0 0 0 0 0 0
Totale 69.947